China and US agree to extend trade tariff truce, says Li
In a challenging market environment, CONMED Corporation (CNMD) stock has reached its 52-week low, dipping to $59.48. The company, with a market capitalization of $1.84 billion and EBITDA of $229.7 million, currently trades at a P/E ratio of 14.05, suggesting potential value opportunity according to InvestingPro analysis. The medical technology company, known for its surgical devices and equipment, has faced significant headwinds over the past year, reflected in a notable 1-year change with a decrease of -25.16%. Despite these challenges, CONMED maintains strong fundamentals with a perfect Piotroski Score of 9 and annual revenue of $1.31 billion. Investors and analysts are closely monitoring CONMED’s performance as it navigates through the pressures affecting the healthcare sector, including regulatory changes and competitive dynamics. The current price level presents a critical juncture for the company, as market participants consider the stock’s valuation and future growth prospects. InvestingPro analysis suggests the stock is currently undervalued, with additional insights and detailed valuation metrics available in the comprehensive Pro Research Report, one of 1,400+ deep-dive analyses available to subscribers.
In other recent news, CONMED Corporation reported fourth-quarter 2024 earnings, with revenue and earnings per share (EPS) surpassing consensus estimates. The company achieved a 6.0% organic revenue growth in the fourth quarter, despite ongoing supply chain challenges, and improved its gross and operating margins. However, CONMED’s guidance for 2025 revenue and EPS fell below expectations, with management attributing this to persistent supply chain issues. In response to the financial updates, Needham maintained a Buy rating but lowered its price target from $97.00 to $91.00, while JPMorgan downgraded the stock from Overweight to Neutral and reduced the target to $70.00. Stifel, on the other hand, upheld its Buy rating with a $72.00 price target, focusing on the growth of CONMED’s Airseal system. Additionally, CONMED announced a quarterly dividend of $0.20 per share, payable on January 3, 2025, reflecting its commitment to shareholder value. In leadership news, Mark Kaye was appointed to CONMED’s Board of Directors, bringing extensive experience in finance and healthcare to the company. These developments collectively highlight CONMED’s current financial and strategic positioning in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.